SCHEMBL1089332

SCHEMBL1089332

CN(CCNc1nccc(N2CCCCCC2)n1)Cc1ccccc1OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2B P18089 1/20 0.50
ADRA2C P18825 1/20 0.50
SLC6A2 P23975 1/20 0.50
HRH2 P25021 1/20 0.50
HTR1D P28221 1/20 0.50
HTR2A P28223 1/20 0.50
HTR2C P28335 1/20 0.50
HTR7 P34969 1/20 0.50
HTR2B P41595 1/20 0.50
HTR5A P47898 1/20 0.50
HTR6 P50406 1/20 0.50
SLC6A3 Q01959 1/20 0.50
TMEM97 Q5BJF2 1/20 0.50
SIGMAR1 Q99720 1/20 0.50
HRH4 Q9H3N8 1/20 0.50
HRH3 Q9Y5N1 1/20 0.50
CARM1 Q86X55 13/20 0.48
PRMT1 Q99873 13/20 0.48
CXCR4 P61073 2/20 0.47
OGA O60502 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1089201 0.87 CXCR4 (0.46) ADRA2BADRA2CSLC6A2HRH2HTR1D
SCHEMBL1089938 0.87 HRH4 (0.51) ADRA2BADRA2CSLC6A2HRH2HTR1D
SCHEMBL1089043 0.86 HRH4 (0.60) ADRA2BADRA2CSLC6A2HRH2HTR1D
SCHEMBL1089665 0.86 HRH4 (0.51) ADRA2BADRA2CSLC6A2HRH2HTR1D
SCHEMBL1089331 0.85 MEN1 (0.54) ADRA2BADRA2CSLC6A2HRH2HTR1D
SCHEMBL1089203 0.82 CXCR4 (0.48) ADRA2BADRA2CSLC6A2HRH2HTR1D
SCHEMBL1089728 0.82 CXCR4 (0.52) ADRA2BADRA2CSLC6A2HRH2HTR1D
SCHEMBL1089896 0.79 HRH4 (0.62) ADRA2BADRA2CSLC6A2HRH2HTR1D
SCHEMBL1089368 0.79 CXCR4 (0.51) ADRA2BADRA2CSLC6A2HRH2HTR1D
SCHEMBL1090240 0.79 CXCR4 (0.47) ADRA2BADRA2CSLC6A2HRH2HTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 US disclosed
US-8153625-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-10 US disclosed
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-02 US disclosed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US disclosed
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 US disclosed
EP-1571146-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 ADRA2B 1173/4885ADRA2C 1318/4885SLC6A2 1133/4885
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof CXCR4, CXCL12, CXCR3 ADRA2B 1173/4885ADRA2C 1318/4885SLC6A2 1133/4885
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 ADRA2B 1173/4885ADRA2C 1318/4885SLC6A2 1133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.